Progen Announces PI-88 Phase 2 Lung Cancer Results
Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone.
